Ciliatech
- Company typePrivate
- Founded2017
- HeadquartersChavanod, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Ciliatech firmographics
Firmographics- Name
- Ciliatech
- Legal name
- CILLIATECH
- Website
- https://cilia.tech
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Ciliatech industry classification
Industry- Product category
- Ophthalmic Surgical Devices / Glaucoma Implants
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
Keywords
Where Ciliatech is headquartered
LocationHeadquarters
- HQ city
- Chavanod
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Ciliatech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales
Revenue model
- Intercil Uveal Spacer Device Sales: Sale of implantable medical devices to healthcare establishments (hospitals, surgical centers) and self-employed healthcare professionals (ophthalmic surgeons). Products are exclusively intended for professional use. Prices set per seller's price list, with commercial conditions defined case-by-case in special terms/contracts.
- European Commercial Launch: Company obtained CE Mark certification in August 2025 and is targeting European commercial launch in H1 2025. First commercial implantations performed in Germany (September 2025) and UK (October 2025).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B professional sales with custom pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Ciliatech product offering
Product offeringCore offering
Ciliatech develops, manufactures, and commercializes the Intercil Uveal Spacer, a non-resorbable Cilioscleral Interpositioning Device (CID) for surgical treatment of glaucoma. The implant is placed between the ciliary body and sclera via an ab-externo approach to lower intraocular pressure (IOP) without entering the anterior chamber or creating a filtration bleb. The company also offers supporting surgeon training via a 3D digital learning platform and an IOP medication washout calculator tool.
Product overview
Ciliatech offers a focused portfolio centered on the Intercil Uveal Spacer (Cilioscleral Interpositioning Device), a novel surgical implant for glaucoma treatment. The company has developed this primary product alongside supporting tools: an IOP Calculator for clinical estimation purposes and a 3D digital learning platform for surgeon training and education. The Intercil device represents a new category of glaucoma surgery known as Cilioscleral Interpositioning, targeting the supraciliary space without penetrating the anterior chamber.
Differentiator
Problem solved
Functional benefit
Products and services
- Intercil Uveal Spacer (CID - Cilioscleral Interpositioning Device) A non-resorbable, one-piece 26% hydrophilic acrylic implant designed to treat glaucoma by positioning between the ciliary body and sclera (cilioscleral interpositioning). The device creates a localized gap to re-establish natural uveoscleral outflow, lowering intraocular pressure without entering the anterior chamber or creating a filtration bleb. Indicated for adult patients (18 years and older) with mild to moderate primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). For use only by trained ophthalmic surgeons.
Quantifiable outcome
- 33% IOP reduction at 36 months with 68% of patients medication-free (SAFARI I & II combined data)
- +4 more outcomes
Companies that use Ciliatech
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Ciliatech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ciliatech partnerships and signals
Strategic signalScale indicators7 records
Recent moves7 records
Expansion highlights6 records
Ciliatech competitors and assessment
Company assessmentEmerging players
- New World Medical: New World Medical develops surgical devices for glaucoma including the Kahook Dual Blade for goniotomy. It is an emerging competitor to Ciliatech in the MIGS and traditional glaucoma surgical space.
- iStar Medical: iStar Medical developed the MINIject supraciliary MIGS implant, directly comparable to Ciliatech's supraciliary approach. It is an emerging European peer with CE Mark and parallel strategic positioning in the same supraciliary space.
Direct peers
- Glaukos Corporation: Glaukos pioneered MIGS with the iStent platform for glaucoma and is the dominant pure-play MIGS company. It directly competes with Ciliatech for surgeon adoption in the same ophthalmic surgical channel, with an established commercial footprint and FDA-cleared products.
- Sight Sciences: Sight Sciences markets the OMNI Surgical System, a MIGS device targeting trabecular and viscoelastic outflow pathways for glaucoma. It is a direct competitor to Ciliatech in the glaucoma surgical device market with a US-focused commercial organization.
Broad incumbents
- Alcon: Alcon acquired Ivantis (Hydrus Microstent) and previously marketed the CyPass Micro-Stent (withdrawn 2018), and has a broad ophthalmic surgical portfolio. It is the dominant incumbent in cataract and surgical glaucoma, with global scale Ciliatech must compete against.
- Ivantis (Alcon): Originally an independent MIGS company developing the Hydrus Microstent for the supraciliary space, Ivantis was acquired by Alcon for $475M. It is directly comparable to Ciliatech as another supraciliary MIGS player, though now operating inside a global incumbent.
- Santen Pharmaceutical: Santen is a Japanese specialty ophthalmology company with a significant glaucoma franchise including both pharmaceuticals and surgical devices (acquired Novagali). It competes with Ciliatech in glaucoma treatment, particularly across EMEA and Asia.
- Bausch + Lomb: Bausch + Lomb (Bausch Health) is a major diversified ophthalmic player offering pharmaceutical, surgical, and vision care products including glaucoma surgical solutions. It provides a competitive backdrop Ciliatech must navigate when targeting hospital purchasing channels.
- Allergan Aesthetics (AbbVie): Allergan's ophthalmology franchise (now AbbVie) commercialized the Xen Gel Stent, a subconjunctival MIGS device for glaucoma. It represents an established competitor in the surgical glaucoma space with deep US sales reach.
- Aerie Pharmaceuticals (Alcon): Aerie Pharmaceuticals focused on glaucoma pharmaceuticals (Rhopressa, Rocklatan) and was acquired by Alcon. It is comparable to Ciliatech as a glaucoma-focused company, though operating in the pharmaceutical rather than surgical device segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Ciliatech compliance and trust
Trust signalCompliance1 record
Ciliatech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ciliatech leadership team
Management profileNumber of profiles
Profiles5 records
Ciliatech subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ciliatech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ciliatech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ciliatech
What does Ciliatech do?
Ciliatech develops, manufactures, and commercializes the Intercil Uveal Spacer, a non-resorbable Cilioscleral Interpositioning Device (CID) for surgical treatment of glaucoma. The implant is placed between the ciliary body and sclera via an ab-externo approach to lower intraocular pressure (IOP) without entering the anterior chamber or creating a filtration bleb. The company also offers supporting surgeon training via a 3D digital learning platform and an IOP medication washout calculator tool.
Is Ciliatech a public or private company?
Ciliatech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ciliatech founded?
Ciliatech was founded in 2017. It employs 11 to 50 people.
Where is Ciliatech based?
Ciliatech is headquartered in Chavanod, France, in the Europe region.
How does Ciliatech make money?
Two revenue lines are on record. Intercil Uveal Spacer Device Sales are the primary driver. The others are european Commercial Launch.
Who are Ciliatech's main competitors?
Emerging players on record are New World Medical and iStar Medical. Direct peers are Glaukos Corporation and Sight Sciences. Broad incumbents are Alcon, Ivantis (Alcon), Santen Pharmaceutical, Bausch + Lomb, Allergan Aesthetics (AbbVie) and Aerie Pharmaceuticals (Alcon).
Does Ciliatech have an API?
No public API is recorded for Ciliatech.
What industry is Ciliatech in?
Ciliatech's product category is Ophthalmic Surgical Devices / Glaucoma Implants. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty). Its NAICS code is 339112 and its SIC code is 3841.